一分钟看懂
这是一项关于淋巴瘤的II 期 / III 期研究，登记的药物或干预包括MK-1045；Rituximab；Rituximab biosimilar；Bendamustine；Cyclophosphamide；Vincristine；Prednisone；Prednisolone；Doxorubicin Hydrochloride，当前状态为招募中。登记地点显示中国北京、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
MK-1045；Rituximab；Rituximab biosimilar；Bendamustine；Cyclophosphamide；Vincristine；Prednisone；Prednisolone；Doxorubicin Hydrochloride · II 期 / III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Beijing Cancer hospital ( Site 0501) · 北京
- Fudan University Shanghai Cancer Center ( Site 0504) · 上海
公开的入选条件
- * Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FL
- * Has radiographically measurable disease per the Lugano Response Criteria.
- * Has provided a newly obtained core or excisional biopsy or archival tissue of a tumor lesion not previously irradiated.
- * If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy (ART).
- * If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks and will continue it.
- * If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07634471；登记信息更新于 2026-09-17。